Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

723.P1.41 Clinical Care - Recurrence, Secondary Neoplasia, and Late Complications after Transplantation Poster I

Sunday, December 7, 2008: 6:00 PM-8:00 PM
Hall A (Moscone Center)
Obesity in Survivors of Childhood Hematopoietic Stem Cell Transplantation

Theodore B. Moore, MD, Leanne Streja*, Pamela Kempert, M.D.*, Alan Ikeda, M.D.*, Kristen Venick, MSN, PNP*, Michael Kwak, M.S.*, Robert Venick, M.D.* and Angela Presson, Ph.D.*

Dept. of Pediatrics, David Geffen School of Medicine at UCLA, Mattel Children's Hospital, Los Angeles, CA

Pre-Transplant Bone Status Evaluation in Patients Undergoing Allogeneic Stem Cell TransplantationClinically Relevant Abstract

Ibrahim Yakoub-Agha, MD, PhD1, Cecile Wibaux2*, Leonardo Magro1*, Audrey Juilliard2*, Isabelle Legroux-Gerot2*, Valerie Coiteux1*, Jean-Pierre Jouet1* and Bernard Cortet2*

1Maladies du Sang, UAM Allogreffes de CSH - EA2686, Lille, France
2Rhumatologie, Lille, France

Long-Term Immune Deficiency (ID) after Allogeneic Stem Cell Transplantation (allo-SCT) Following a Myeloablative (MA) Conditioning Regimen

Elise Corre1*, Maryvonnick Carmagnat2*, Marc Busson2*, Regis Peffault de Latour1*, Marie Robin1*, Patricia Ribaud1*, Antoine Toubert2*, Claire Rabian2* and Gerard Socie1

1Hematology / Transplantation, Hospital Saint Louis, Paris, France
2Immunology, Hospital Saint Louis, Paris, France

Longitudinal Trends in Peripheral Blood Parameters Predict Development of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia (t-MDS/AML) after Autologous Transplantation for Lymphoma

Liton Francisco*, Can-Lan Sun, Lester Laddaran*, Melanie Sabado*, Alysia Bosworth*, Karen L. Chang, Leslie Popplewell, Auayporn P. Nademanee, Marilyn L. Slovak, Stephen J. Forman, Ravi Bhatia and Smita Bhatia

City of Hope National Medical Center, Duarte, CA

Quantification by Superconducting Quantum Interference Device (SQUID) of Iron Overload after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Alessandro Busca, MD1, Michele Falda1*, Paola Manzini1*, Sergio D'antico1*, Franco Locatelli1*, Annalisa Chiappella2*, Stefano D'Ardia1*, Filomena Longo, MD3*, Roberto Calabrese4* and Antonio Piga, MD4

1Ospedale Maggiore San Giovanni Battista, Torino, Italy
2Hematology 2, AOU San Giovanni Battista, Turin, Italy
3Biological and Clinical Sciences, University of Turin, Turin, Italy
4Dipartimento Science Pediatriche, Torino University, Torino, Italy

Bone Complications Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Prospective Study

Anna D Petropoulou, MD1, Marie Robin, MD1*, Andrée-Laure Herr, MD1*, Agnes Devergie, MD1*, Regis Peffault De Latour, MD1*, Philippe Orcel, Prof2* and Gérard Socié, Prof3*

1Bone Marrow Transplantation, Saint-Louis Hospital, Paris, France
2Rhumatology, Lariboisière Hospital, Paris, France
3Bone Marrow Transplantation, Saint Louis Hospital, Paris, France

Pulmonary Function in Pediatric survivors of non-Malignant Disorders after Allogeneic Hematopoietic Stem Cell Transplantation

Megan S Motosue1*, Hiroto Inaba, MD, PhD1, Jianmin Pan, PhD2*, Dennis C. Stokes, MD3*, Deo Kumar Srivastava, PhD2*, Kimberly A. Kasow, DO1*, Gregory A. Hale, MD1 and Wing Leung, MD, PhD1*

1Oncology, St. Jude Children's Research Hospital, Memphis, TN
2Biostatistics, St. Jude Children's Research Hospital, Memphis, TN
3Pulmonary Medicine, St. Jude Children's Research Hospital, Memphis, TN

Late Pulmonary Dysfunction in Long-Term Survivors after allogeneic  Hematopoietic Stem Cell Transplantation with Intensified Conditioning Regimen Including Thiotepa, Cyclophosphamide, and Total Body Irradiation

Satomi Ito1*, Maki Hagihara1*, Kenji Motohashi1*, Atsuo Maruta1*, Yoshiaki Ishigatsubo2* and Heiwa Kanamori, MD, PhD1

1Hematology, Kanagawa Cancer Center, Yokohama, Japan
2Internal Medicine and Clinical ImmunologY, Yokohama City University Graduate School of of Medicine, Yokohama, Japan

High Prevalence of Vitamin D Deficiency in Allogeneic Stem Cell Transplant Recipients

Richard W Joseph Jr., MD1*, Krishna V. Komanduri, M.D.2*, R. M Saliba, MD3*, Amin Alousi, MD4, S. Giralt5*, Gabriela Rondon6*, Joyce Neumann7*, Cindy Trevino, APN3*, Daniel R. Couriel, MD8, Richard Champlin9* and U. Popat5*

1Department of Stem Cell Transplant and Cellular Therapy, MD Anderson Cancer Center, Houston, TX
2Adult Stem Cell Transplant Program, Department of Medicine, University of Miami, Miami, FL
3BMT Unit 423, UT M.D. Anderson Cancer Ctr., Houston, TX
4Dept. of Stem Cell Transplantation, UTMD Anderson Cancer Center, Houston, TX
5Hem/Onc., MD Anderson Cancer Ctr., Houston, TX
6Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX
7Department of Stem Cell Transplantation & Cell Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
8Sarah Cannon Cancer Center, Tennessee Oncology, Nashville, TN
9Stem Cell Transplant Program, Department of Medicine, University of Texas, Miami, FL

The Prevalence of 25-Hydroxyvitamin D Deficiency in Post-HSCT Pediatric Patients

Christine Duncan, MD, MSc1*, Lynda Vrooman, MD1*, Lori Bechard, RD, LDN2*, Elly Barry, MD, MSc1 and Leslie E. Lehmann, MD1*

1Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
2Gastroenterology/Nutrtion, Children's Hospital Boston, Boston, MA

Genomic Instability Is Frequent in Oral and Rare in Nasal Mucosal Cells of Allogeneic HCT Recipients

Faisal Khan, PhD1*, Sarah Sy1*, Polly Louie1*, Robyn Lee1*, Douglas A. Stewart, MD, FRCPC2, James A. Russell2 and Jan Storek, MD, PhD1

1University of Calgary, Calgary, AB, Canada
2Tom Baker Cancer Centre, Calgary, AB, Canada

Efficacy of Imatinib Mesylate in the Treatment of Refractory Sclerodermatous Chronic Graft-Versus-Host DiseaseClinically Relevant Abstract

Ibrahim Yakoub-Agha, MD, PhD1, Leonardo Magro, MD1*, Benoit Catteau, MD2*, Christophe Willekens1*, Valerie Coiteux, MD1*, Benedicte Bruno, MD3*, Louis Terriou1* and Jean-Pierre Jouet, MD1*

1Maladies du Sang, UAM Allogreffes de CSH - EA2686, Lille, France
2Dermatologie, Lille, France
3Pediatrie, Lille, France

Long Term Follow-up and Matched Pair Analysis of Adjuvant Donor Lymphocyte Transfusions Following Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-Risk AML

Michael Schleuning1, Christoph Schmid2*, Christian Koenecke3*, Bernd Hertenstein4*, Herrad Baurmann1*, Rainer Schwerdtfeger1 and Hans-Jochem Kolb5*

1Centre for hematopoietic cell transplantation, German Diagnostic Clinic, Wiesbaden, Germany
22. Medizinische Klinik, Zentralklinikum Augsburg
3Dept. of Hematology/Oncology, Hannover Medical School
4Klinikum Bremen Mitte
5Department of Medicine, University of Munich

5–azacitidine Treatment of Imminent Relapse Defined by Decreasing Donor CD34+ Progenitor Subset Chimerism in Patients with CD34+ High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) after Allogeneic Stem Cell Transplantation

Uwe Platzbecker1, Joergen Radke2*, Alexander Kiani2*, Malte Bonin2*, Eray Goekkurt2*, Uta Oelschlägel2*, Brigitte Mohr2*, Gerhard Ehninger, MD3, Martin Bornhauser, MD1* and Christian Thiede2*

1University Hospital Dresden, Dresden, Germany
2Hematology, University Hospital, Dresden, Germany
3Universitatsklinikum Carl Gustav Carus, Dresden, Germany

The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Predicts Survival and Non-Relapse Mortality in Lymphoma and Myeloma Patients Undergoing Reduced-Intensity or Non-Myeloablative Allogeneic Stem Cell Transplantations   

Lucia Farina1*, Benedetto Bruno2*, Francesca Patriarca3*, Francesco Spina1*, Roberto Sorasio4*, Mara Morelli1*, Renato Fanin3*, Mario Boccadoro4* and Paolo Corradini, MD1

1Hematology - BMT, Istituto Tumori, University of Milano, Milano, Italy
2University of Torino, Torino, Italy
3Hematology, University of Udine, Italy
4Hematology, Ospedale San Giovanni Battista, University of Turin, Italy

High-Dose Therapy with Peripheral Blood Stem Cell Transplantation for Patients with Relapsed or Refractory Hodgkin’s Disease: A Single-Institution 20-Year Follow-up Experience

Kai Neben, MD1*, Julia Meissner, MD1*, Sascha Dietrich, MD1*, Manfred Hensel, MD2, Alwin Krämer, MD3*, Mathias Witzens-Harig, MD4*, Peter Dreger, MD1* and Anthony D. Ho, MD5*

1Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany
2Mannheimer Onkologie Praxis, Mannheim, Germany
3Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (dkfz), Heidelberg, Germany
4Hematology and Oncology, Medizinische Klinik V, Heidelberg, Germany
5Med. Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany

Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

Mohamed L. Sorror, MD, MS1*, Barry Storer, PhD1*, Brenda M. Sandmaier, MD1*, Michael Maris, MD1*, Thomas Chauncey, MD2*, Richard T. Maziarz, MD3, Michael Pulsipher, MD4, Judith Shizuru, MD, PhD5*, Dietger Niederwieser, MD6*, Edward Agura, MD7, James C. Wade, MD, MPH8, Amelia A Langston, MD9, Rainer F. Storb, MD1 and David G. Maloney, MD, PhD1*

1Fred Hutchinson Cancer Research Center/ University of Washington, Seattle, WA
2VA Puget Sound Health Care System/ Fred Hutchinson Cancer Research Center/ University of Washington, Seattle, WA
3Oregon Health & Science University, Portland, OR
4University of Utah Medical Center, Salt Lake City, UT
5Stanford University Medical Center, Stanford, CA
6University of Leipzig, Leipzig, Germany
7Baylor University Medical Center, Dallas, TX
8Medical College of Wisconsin, Milwaukee, WI
9School of Medicine, Emory University, Atlanta, GA

Isolated Extra-Medullary Relapse of Acute Leukemia after Allogeneic Stem-Cell Transplantation; Different Kinetics and Better Prognosis Than Systemic Relapse

Avichai Shimoni*, Avital Rand*, Izhar Hardan*, Noga Shem-Tov*, Etai Zilbershatz*, Ronit Yerushalmi* and Arnon Nagler

Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel

Treosulfan Compared to Total Body Irradiation-Based Preparative Regimens Before Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia : A Retrospective Long-Term Study

Dietrich Wilhelm Beelen, MD1*, Tanja Gromke, MD1*, Rudolf Trenschel, MD1*, Inken Hilgendorf, MD2*, Daniel Wolff, MD2*, Ahmet Elmaagacli, MD1, Mathias Freund, MD2* and Jochen Casper, MD2*

1Department of Bone Marrow Transplantation, University Hospital Essen, Essen, Germany
2Department of Hematology and Oncology, University Hospital of Rostock, Rostock, Germany

*signifies non-member of ASH